Clinical Nanomedicine: A Solution to the Chemotherapy Conundrum in Pediatric Leukemia Therapy

Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers

(2014) M. Montana et al.   JOURNAL OF CHEMOTHERAPY

Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel

(2013) Hongmei He et al.   BIOMATERIALS

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

(2013) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Filomicelles in nanomedicine – from flexible, fragmentable, and ligand-targetable drug carrier designs to combination therapy for brain tumors

(2013) Núria Sancho Oltra et al.   Journal of Materials Chemistry B

Targeted polymeric therapeutic nanoparticles: design, development and clinical translation

(2012) Nazila Kamaly et al.   CHEMICAL SOCIETY REVIEWS

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia

(2012) E.J. Feldman et al.   LEUKEMIA RESEARCH

Dexamethasone-Loaded Block Copolymer Nanoparticles Induce Leukemia Cell Death and Enhance Therapeutic Efficacy: A Novel Application in Pediatric Nanomedicine

(2012) Vinu Krishnan et al.   MOLECULAR PHARMACEUTICS

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

(2012) J. Hrkach et al.   Science Translational Medicine

Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis

(2011) U. Fasol et al.   ANNALS OF ONCOLOGY

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours

(2011) R Plummer et al.   BRITISH JOURNAL OF CANCER

Paclitaxel poliglumex for ovarian cancer

(2011) Vijaya L Galic et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

(2011) Ken Kato et al.   INVESTIGATIONAL NEW DRUGS

Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum

(2011) Jae-Lyun Lee et al.   INVESTIGATIONAL NEW DRUGS

Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA

(2011) Tatsuaki Tagami et al.   JOURNAL OF CONTROLLED RELEASE

Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance

(2011) Lisa M. Kaminskas et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Noninvasive, Transient and Selective Blood-Brain Barrier Opening in Non-Human Primates In Vivo

(2011) Fabrice Marquet et al.   PLoS One

More Effective Nanomedicines through Particle Design

(2011) Jin Wang et al.   Small

Overcoming in vivo barriers to targeted nanodelivery

(2011) Adrian Chrastina et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects

(2010) Hiroshi Maeda   BIOCONJUGATE CHEMISTRY

Phase I Study of NK012, a Novel SN-38-Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors

(2010) T. Hamaguchi et al.   CLINICAL CANCER RESEARCH

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

(2010) Juan W. Valle et al.   INVESTIGATIONAL NEW DRUGS

Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies

(2009) W. C. Zamboni et al.   CLINICAL CANCER RESEARCH

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic

(2009) Mark E. Davis   MOLECULAR PHARMACEUTICS

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report

(2009) Anne L. Angiolillo et al.   PEDIATRIC BLOOD & CANCER

Effect of Surface Properties on Nanoparticle–Cell Interactions

(2009) Ayush Verma et al.   Small

Update on developmental therapeutics for acute lymphoblastic leukemia

(2009) Malcolm A. Smith   Current Hematologic Malignancy Reports

Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study

(2008) R. Mody et al.   BLOOD

Particle size-dependent triggering of accelerated blood clearance phenomenon

(2008) Hiroyuki Koide et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process

(2008) I. Hamad et al.   MOLECULAR IMMUNOLOGY

Nanoparticle-mediated cellular response is size-dependent

(2008) Wen Jiang et al.   Nature Nanotechnology

Nanoparticle therapeutics: an emerging treatment modality for cancer

(2008) Mark E. Davis et al.   NATURE REVIEWS DRUG DISCOVERY